齐拉西酮对首发青少年精神分裂症患者脑神经功能和结构的影响

Effect of Ziprasidone on Brain Neurological Function and Structure in First-episode Adolescent Schizophrenic Patients

关键词:  青少年  精神分裂症  脑灰质结构  认知功能

Key words:  adolescent  schizophrenia  gray body structure  cognitive function

摘要:

目的 探讨齐拉西酮治疗首发青少年精神分裂症对患者神经元功能改善和脑灰质结构的影响。方法 选取徐州市东方人民医院2017年4月-2018年4月精神科确诊为首发精神分裂症青少年患者92例作为研究对象，依据随机原则分成2组，对照组46例仅行心理治疗，观察组46例口服齐拉西酮治疗，连续治疗6个月，对比2组患者治疗前后血清神经细胞因子、神经电生理参数以及脑灰质体积的变化。结果 治疗前2组患者脑源性神经营养因子（BDNF）、胶质源性神经营养因子（GDNF）等神经营养因子指标，P300、N2-P3电生理参数差异无统计学意义。治疗1个月、2个月时观察组4项指标改善优于对照组（P<0.05）；6个月后观察组患者右侧颞上回、右侧颞中回体积均略有增加，与对照组比较差异有统计学意义（P<0.05）。结论 齐拉西酮治疗首发青少年精神分裂症能够有效改善神经元功能，调节神经电生理功能，缓解其脑灰质结构障碍，逐渐恢复患者的认知能力。

Abstract:

OBJECTIVE To investigate the effect of ziprasidone on the improvement of neuronal function and gray matter structure in patients with first-episode schizophrenia. METHODS A total of 92 adolescents with schizophrenia diagnosed as the psychiatric department from April 2017 to April 2018 were enrolled in Xuzhou Oriental People's Hospital. The patients were divided into two groups according to the random principle. The control group was only treated with psychotherapy in 46 cases. Forty-six patients were treated with oral ziprasidone for 6 months. The changes of serum neurocytokines, neurophysiological parameters and gray matter volume were compared before and after treatment. RESULTS There were no significant differences in GDNF, BDNF and other neurotrophic factors, P300, N2-P3 electrophysiological parameters between the two groups before treatment. The improvement to 4 indicators in the observation groups at 1st month and 2nd months of treatment compared with the control group(P<0.05). After 6 months, the volume of the right upper iliac crest and the right iliac crest was slightly increased from the observation group, and the difference was statistically significant(P<0.05). CONCLUSION Ziprasidone treatment of first-episode schizophrenia can effectively improve neuronal function, regulate neurophysiological function, alleviate the structural disorder of gray matter, and gradually restore the cognitive ability of patients.